Formulary monograph
Tovecimig
Monograph section
| Field | Value |
|---|---|
| Drug | Tovecimig (CTX-009 and ABL001) |
| Indication reviewed | Second-line advanced biliary tract cancer |
| Therapeutic category | Bispecific antibodies targeting DLL4 and VEGF-A |
| Manufacturer | Compass Therapeutics |
| Regulatory status | Not approved in any country. FDA Fast Track designation granted April 2024 and orphan drug designation granted April 2026; FDA recommended in September 2026 a trial demonstrating a survival benefit before a biologics license application submission; the company continues to prepare one |
| Data as of | November 17, 2026 |
| Review status | Draft for pharmacy and therapeutics committee review |
Introduction
Disease background
Definition: biliary tract cancer and the anatomical subtypes of cholangiocarcinoma
“Biliary tract cancer is a term that includes cholangiocarcinoma (either intrahepatic or extrahepatic in origin) and cancers of the gallbladder and ampulla of Vater. These uncommon cancers arising from the biliary tract account for less than 1% of all cancers worldwide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biliary tract cancer (BTC), including cholangiocarcinoma, gallbladder cancer, and (to a lesser degree) ampullary tumours, are aggressive malignancies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cholangiocarcinoma (CCA) constitutes a diverse group of malignancies emerging in the biliary tree. CCAs are divided into three subtypes depending on their anatomical site of origin: intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) CCA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“iCCAs arise above the second-order bile ducts, whereas the point of anatomical distinction between pCCA and dCCA is the insertion of the cystic duct.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the USA, pCCA is the single largest group, accounting for approximately 50–60% of all CCAs, followed by dCCA (20–30%) and iCCA (10–20%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incidence in the United States
| Cancer site | Estimated new cases, both sexes | Estimated deaths, both sexes |
|---|---|---|
| Liver and intrahepatic bile duct | “42,340”View highlighted excerpt for this quote | “30,980”View highlighted excerpt for this quote |
| Gallbladder and other biliary | “12,640”View highlighted excerpt for this quote | “4590”View highlighted excerpt for this quote |
| All sites | “2,114,850”View highlighted excerpt for this quote | “626,140”View highlighted excerpt for this quote |
“From 2001-2017, CCA, iCCA, and eCCA incidence (per 100 000 person-years) increased 43.8% (3.08 to 4.43), 148.8% (0.80 to 1.99), and 7.5% (2.28 to 2.45), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall age-adjusted incidence of CCA from 2001 to 2017 was 3.65 per 100 000 p-y (iCCA, 1.19; eCCA, 2.46).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence and the proportion of participants who reach second-line therapy
“Patients with advanced biliary tract cancer often experience a rapid decline in performance status following progression on first-line chemotherapy, and only 15–25% receive second-line therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 413 patients, 84.5% received gemcitabine-based first-line (1L) treatment, 46% received second-line treatment, and 16.5% received third-line (3L) treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 46% (n = 190) of patients initiated second line of therapy (2LOT), which predominantly involved 5-fluorouracil (5FU)-based mono- or combination chemotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
The second-line population: progression after first-line chemotherapy and immunotherapy
“Patients were eligible if they were aged 18 years or older and had histologically or cytologically verified locally advanced or metastatic biliary tract cancer (including cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma) with documented radiological disease progression to previous first-line cisplatin and gemcitabine chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In all enrolled patients, the primary tumour sites were intrahepatic cholangiocarcinoma (in 72 [44%] of 162 patients), extrahepatic cholangiocarcinoma (45 [28%]), gallbladder (34 [21%]), and ampullary cancer (11 [7%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More recently, the addition of immune checkpoint inhibitors [specifically durvalumab (TOPAZ-1 trial3) and pembrolizumab (KEYNOTE-966 trial4)] to cisplatin–gemcitabine has demonstrated significant improvements in overall survival (OS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, for ∼60% of patients diagnosed with ABC, there is currently no targetable alteration identified; thus second-line therapy options will be limited to further cytotoxic chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Signs and symptoms
“CCAs are usually asymptomatic during early stages. The most frequent symptom of pCCA and dCCA is jaundice due to biliary tract obstruction88. In iCCA, jaundice is less frequent and mostly associated with advanced disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with pCCA and dCCA typically present with painless jaundice owing to underlying biliary obstruction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: late presentation, stage at diagnosis, and survival from diagnosis
“CCAs are usually asymptomatic in early stages and, therefore, often diagnosed when the disease is already in advanced stages, which highly compromises therapeutic options, resulting in a dismal prognosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite advances in CCA awareness, knowledge, diagnosis and therapies, patient prognosis has not improved substantially in the past decade, with 5-year survival (7–20%) and tumour recurrence rates after resection still disappointing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prognosis is poor, with an all-stage 5-year overall survival of less than 20%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients are rarely diagnosed with early-stage disease and therefore curative surgery and adjuvant therapy is only feasible for a small proportion of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median overall survival from diagnosis was 8, 6, 9, and 2 months for CCA, iCCA, eCCA, and CUP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The annual mortality rate declined from 45.2% in 2001 to 38.7% in 2016 for CCA, and from 57.1% in 2001 to 41.2% in 2016 for iCCA, but the rates for iCCA remained consistently higher than for eCCA, which generally remained stable (40.9% in 2001 vs 37.0% in 2016; Fig. 2F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival after progression on first-line therapy
“Median overall survival was 6·2 months (95% CI 5·4–7·6) in the ASC plus FOLFOX group versus 5·3 months (4·1–5·8) in the ASC alone group (adjusted HR 0·69 [95% CI 0·50–0·97], p=0·031; figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall survival rate in the ASC alone group was 35·5% (95% CI 25·2–46·0) at 6 months and 11·4% (5·6–19·5) at 12 months, compared with 50·6% (39·3–60·9) at 6 months and 25·9% (17·0–35·8) at 12 months in the ASC plus FOLFOX group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival was 4·0 months (95% CI 3·2–5·0; appendix p 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause mortality was 53% with a median survival of 11.5 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS time from first presumed BTC diagnosis was 13.3 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median time on 2LOT was 3.6 months and was longer for patients with stage III disease (4.6 months) than for patients with stage IV and stage I/II disease (3.6 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden: quality of life, healthcare costs, and work loss
“Exposure to FOLFOX did not have a significant impact on the time to Global Health Scale deterioration (n = 76 participants; 36 patients ASC-alone arm; 40 patients in the FOLFOX arm), with similar TTD in both arms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“aHR 0.97, 95% CI 0.48-1.97, P = 0.937” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Addition of FOLFOX to ASC did not appear to induce worsening of the QoL parameters assessed (Table 3) at 4 months of study entry. In contrast, patients in the ASC-alone arm appeared to experience worsening of the EQ-5D utility values and most of the QLQ-C30 scales (including global, physical, social, and role scales), whereas these were stable in the FOLFOX arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean PPPM costs for the overall population were $18,274 for all-cause costs, of which approximately 84% ($15,296) comprised BTC-related costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The total mean (SD) PPPM all-cause costs by LOT were $19,589 ($22,603) for 1LOT, $22,617 ($19,302) for 2LOT and $33,534 ($40,588) for 3LOT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary driver of costs across all three LOTs was outpatient (including antineoplastic therapy visits) and inpatient utilization followed by outpatient pharmaceutical costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One thousand and sixty-five patients with CCA were included (iCCA: n = 624 [58.6%]; eCCA: n = 380 [35.7%]). The mean age was 51.9-53.9 years across cohorts. In patients with iCCA and eCCA, respectively, the number of mean all-cause days absent PPPM for illness was 6.0 and 4.3, and 12.9 and 6.6% had ≥1 CCA-related short-term disability claim. Median indirect costs PPPM owing to absenteeism, short-term disability, and long-term disability, respectively, in patients with iCCA were $622, $635, and $690, and $304, $589, and $465 in patients with eCCA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the absenteeism, short-term disability, and long-term disability cohorts, respectively, mean indirect costs associated with productivity loss contributed to 8.6, 7.2, and 6.7% of the total costs ($11,287, $11,887, and $11,977).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This suggests that patients in our analysis are more economically advantaged than the overall population of the United States, many of whom do not have access to paid sick leave or are not provided with insurance by their employers. Thus, our analysis may underestimate the productivity losses within the overall population of the United States.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Development and regulatory status
Investigational status: tovecimig is a product candidate with no marketing approval
Current development phase: randomized phase 2/3 COMPANION-002 trial
Trial sites and enrollment
Prior clinical development completed in South Korea
Investigator-sponsored trials in progress
United States: Fast Track designation
United States: orphan drug designation
Regulatory status: BLA in preparation after FDA feedback in September 2026
Launch: anticipated in 2027
Pharmacology and usage
Mechanism of action
Dual target: DLL4 and VEGF-A
Molecular format: anti-VEGF antibody backbone linked to DLL4-binding single-chain variable fragments
Rationale for adding DLL4 blockade to VEGF blockade
“VEGF/VEGFR blockade can inhibit VEGF-driven tumor angiogenesis, and the regression of tumor vessels is dependent on the VEGF signaling pathway. However, VEGF inhibitors alone are not capable of destroying all tumor blood vessels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several preclinical xenograft studies have demonstrated that DLL4/Notch blockade inhibited tumor progression by promoting hyperproliferation of endothelial cells, which resulted in an increase in vascular density and a decrease in functional tumor vasculature” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hence, given that the VEGF/VEGFR signal transduction pathway and the DLL4/Notch signal transduction pathway affect angiogenesis via different mechanisms of action, CTX-009 was designed to block both pathways in a novel therapeutic format” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Target biology in biliary tract cancer
“VEGF-A overexpression has been reported in BTC, correlating with stage, the presence of metastases and prognosis of the disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DLL4 is highly expressed in BTC and up-regulation of DLL4 expression is associated with poor survival in patients with BTC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, DLL4-Notch 1 signaling can be a part of the development of resistance to anti-VEGF therapeutics” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Preclinical antitumor activity in gastric and colon cancer xenograft models
“Both bispecific antibodies, mABL001 and ABL001, inhibited tumor progression in the tested xenograft models at doses ranging from 1 to 6.5 mg/kg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The anti-cancer effects of mABL001 or ABL001 monotherapy were calculated as %TGI ranging from 27.4% to 57.2%, depending on the doses of mABL001 or ABL001 and cancer cell lines in xenograft models” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect on tumor vasculature and on target expression in tumor endothelium
“Based on the results of immunohistochemical analysis of tumor blood vessels, the expression levels of VEGFR-2 and DLL4, dual targets of ABL001, were markedly reduced in tumor endothelial cells after ABL001 treatment compared to that of CD31, a conventional endothelial cell marker.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The combination treatment synergistically inhibited tumor progression compared to each monotherapy. More tumor vessel regression and apoptotic tumor cell induction were observed in tumors treated with the combination therapy, which might be due to tumor vessel normalization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical pharmacodynamic or target-engagement biomarkers
No evidence found.
Pharmacokinetics
Population pharmacokinetic model in patients with solid tumors
“A total of 712 plasma concentrations from 30 patients with relapsed or refractory solid tumors were collected from a phase 1 study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PK of ABL001/CTX‐009 was well described by a two‐compartment model with a parallel first‐order and Michaelis–Menten elimination kinetics. Body weight was selected as a significant covariate on V1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Model parameter estimates
| Parameter | Estimate (relative standard error, %) |
|---|---|
| Clearance, L/h | “0.0184 (18)”View highlighted excerpt for this quote |
| Central volume of distribution, L | “3.87 (5)”View highlighted excerpt for this quote |
| Intercompartmental clearance, L/h | “0.0207 (16)”View highlighted excerpt for this quote |
| Peripheral volume of distribution, L | “1.31 (28)”View highlighted excerpt for this quote |
Elimination half-life and time to steady state
Simulated exposure: fixed dosing compared with weight-based dosing and alternative intervals
“Simulations after administrations of fixed or weight‐based doses showed similar plasma concentrations. Additionally, 10 mg/kg for every other week and 15 mg/kg for every three‐week administration showed comparable plasma concentrations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When comparing the optimal dosing strategy, the ABL001/CTX‐009 plasma concentrations administered every 2 weeks of 10 mg/kg and every 3 weeks of 15 mg/kg showed similar average plasma concentrations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Simulated regimen | Maximal plasma concentration, mg/L | Average plasma concentration at steady state, mg/L |
|---|---|---|
| Fixed dose, 700 mg | “263.1 ± 68.5”View highlighted excerpt for this quote | “123.9 ± 65.2”View highlighted excerpt for this quote |
| Weight-based dose, 10 mg/kg | “232.3 ± 68.8”View highlighted excerpt for this quote | “111.3 ± 66.0”View highlighted excerpt for this quote |
| 15 mg/kg every 3 weeks | “296.1 ± 77.4”View highlighted excerpt for this quote | “107.6 ± 68.5”View highlighted excerpt for this quote |
Immunogenicity and pharmacokinetics in organ impairment
No evidence found.
Indications
Investigational product with no approved indication: population under study in COMPANION-002
Investigational use covered by the FDA Fast Track designation
Investigational use covered by the FDA orphan drug designation
Investigational setting: size of the second-line population without an approved targeted option
Investigational product currently under evaluation in a randomized phase 2/3 trial
Dosing and administration
COMPANION-002 regimen: tovecimig dose and schedule with the paclitaxel backbone
Route and schedule recorded in the registry
| Field | Quoted record |
|---|---|
| Experimental arm | “CTX-009 plus Paclitaxel” |
| CTX-009 administration | “IV infusion on day 1 and 14 of every 28 day cycle” |
| Paclitaxel administration | “IV infusion on day 1, 8, and 15 of every 28 day cycle” |
Infusion preparation and duration in the phase 1 study
“Patients received an intravenous infusion of ABL001/CTX‐009 diluted in 0.9% normal saline (250 mL) over 1 h. ABL001/CTX‐009 was administered in a 2‐week cycle, with the exception of the second dose, which had a 3‐week interval. Administration continued until unacceptable toxicity or disease progression was identified according to RECIST version 1.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 1 dose escalation range and starting dose
Dose levels at which responses were observed in the phase 1 study
Alternative dosing strategies supported by simulation
“Based on the simulation results, ABL001/CTX‐009 can be administered as a fixed dose and with a longer dosing interval for follow‐up studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Simulation results comparing fixed dosing (700 mg) and weight‐base dosing (10 mg/kg) showed comparable PK properties of ABL001/CTX‐009, supporting the suitability of a non‐weight‐based dosing of ABL001/CTX‐009.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Premedication, dose modification, and dosing in organ impairment
No evidence found.
Clinical efficacy summary
COMPANION-002
Design and population
Registered purpose of the trial
Registered design details
| Design feature | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Single (Outcomes Assessor)” |
Blinded independent central review of the primary endpoint
Randomization ratio and stratification factors
“Patients are randomized to a 2:1 ratio, and crossover is allowed to the experimental arm at the time of progression in the control arm for patients that continue to meet eligibility criteria. Stratification factors include stage (locally advanced vs metastatic), anatomic subtype of the primary tumor (intrahepatic cholangiocarcinoma vs other) and ECOG performance status (0 or 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Crossover from the control arm
Dosing of both arms as reported by the sponsor
Key inclusion criteria: registry record
Exclusion of participants eligible for an approved targeted therapy
Balance of baseline characteristics between arms
Baseline demographics and disease characteristics, n (%) unless stated
| Characteristic | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) |
|---|---|---|
| Median age, years | “65.0” | “63.0” |
| Male | “53 (47.7)” | “24 (42.1)” |
| Female | “58 (52.3)” | “33 (57.9)” |
| Asian | “17 (15.3)” | “10 (17.5)” |
| White | “84 (75.7)” | “40 (70.2)” |
| African American | “4 (3.6)” | “6 (10.5)” |
| Unknown or other race | “6 (5.4)” | “1 (1.8)” |
| Intrahepatic primary location | “62 (55.9)” | “30 (52.6)” |
| Other primary location (extrahepatic, gallbladder, ampullary) | “49 (44.1)” | “27 (47.4)” |
| ECOG performance status 0 | “53 (47.7)” | “27 (47.4)” |
| ECOG performance status 1 | “58 (52.3)” | “30 (52.6)” |
| Locally advanced disease | “12 (10.8)” | “5 (8.8)” |
| Metastatic disease | “99 (89.2)” | “52 (91.2)” |
Endpoints
Registered primary outcome measure
Registered secondary outcome measures
Endpoint definitions in the trial design publication, including the quality-of-life instrument
“The primary end point is ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by independent central review (ICR). The secondary end points are progression free survival, duration of response, overall survival, disease control rate, safety and quality of life measured with EORTC QLQ-C30.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Event threshold triggering the time-to-event analyses
Efficacy results
Primary endpoint: objective response rate as first reported
Primary endpoint: objective response rate in the final analysis
Best overall response by blinded independent central review, intent-to-treat population
| Best overall response | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) |
|---|---|---|
| Overall response rate (complete plus partial response) | “19 (17.1%)” | “3 (5.3%)” |
| Complete response | “1 (0.9%)” | “0 (0.0%)” |
| Partial response | “18 (16.2%)” | “3 (5.3%)” |
| Stable disease | “49 (44.1%)” | “19 (33.3%)” |
| Non-complete response / non-progressive disease | “9 (8.1%)” | “2 (3.5%)” |
| Progressive disease | “18 (16.2%)” | “24 (42.1%)” |
| Not evaluable | “16 (14.4%)” | “9 (15.8%)” |
Key secondary endpoint: progression-free survival
Key secondary endpoint: overall survival in the intent-to-treat population
Efficacy summary with hazard ratios and two-sided p values
| Endpoint | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) | Hazard ratio | Two-sided p value |
|---|---|---|---|---|
| Overall response rate | “19 (17.1%)” | “3 (5.3%)” | Not reported | “p=0.031” |
| Progression-free survival, months | “4.7” | “2.6” | “0.44” | “p<0.0001” |
| Overall survival, intent-to-treat, months | “8.9” | “9.4” | “1.05” | “p=0.78” |
| Overall survival, crossover-adjusted by rank-preserving structural failure time, months | “8.9” | “9.4” | “1.13” | “p=0.65” |
Prespecified secondary analysis of progression-free survival before and after crossover
Post hoc analysis of overall survival within the control arm
Post hoc analysis of progression-free survival within the control arm
Post hoc pooled overall survival of all participants who received tovecimig
Limitations
Crossover as the stated reason the overall survival endpoint was not met
Stated non-fulfilment of the crossover-adjusted analysis assumptions
Prespecified status of the analysis whose assumptions were not met
ABL001-P1bC
Design and population
Single-arm phase 2 design in the second- and third-line setting
Origin of the biliary tract cancer cohort
“A phase Ib study conducted in South Korea, evaluated CTX-009 in combination with either irinotecan or paclitaxel in patients with metastatic or advanced solid tumors. Two out of three patients with cholangiocarcinoma who received CTX-009 in combination with paclitaxel achieved confirmed PRs. This observation in the phase Ib study led to the addition of a phase II cohort that enrolled patients with BTC who were treated in the second- or third-line setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants enrolled, anatomic subtype, and line of therapy
“A total of 24 patients were enrolled: nine (37%) with intrahepatic cholangiocarcinoma, three (13%) with extrahepatic cholangiocarcinoma, seven (29%) with gallbladder cancer and five (21%) with ampullary carcinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endpoints
Registered primary outcome measures
Primary and secondary objectives as reported at the congress
Efficacy results
Response and survival outcomes as reported at the congress
Response and survival outcomes as summarized in the trial design publication
“The primary end point of the phase II study was overall response rate (ORR) and the ORR was 37.5% (n = 9/24 patients). Among 11 patients treated in the second-line, the ORR was 63.6% (n = 7/11) versus 15% (n = 2/13) among patients treated in the third-line setting. The median duration of response was 6.9 months, and responses were seen in patients with all anatomic subtypes of BTC, including ampullary cancer. The median progression-free survival was 9.4 months and the survival rate at 1 year was 53%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations
No evidence found.
2024-0279
Design and population
Study dates, status, and site
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2025-01-22” |
| Primary completion (estimated) | “2027-05-01” |
| Enrollment (estimated) | “50” |
| Recruitment status | “Recruiting” |
| Last update posted | “2026-09-09” |
Key inclusion criteria
| Criterion | Quoted registry text |
|---|---|
| Age | “Age ≥ 18 years.” |
| Diagnosis and prior therapy | “Histologically or cytologically confirmed (outside pathology reports will be accepted) unresectable advanced, metastatic, or recurrent BTC at the time of enrollment that has not been previously treated in the metastatic setting.” |
| Performance status | “ECOG performance status ≤2” |
Sponsor description of the investigator-sponsored trial
Endpoints
Registered primary outcome measure
Primary and secondary objectives
Efficacy results
No evidence found.
Limitations
No evidence found.
NOV150101-101
Design and population
Open-label dose escalation and dose expansion design
Route, infusion duration, and dosing interval
“Patients received an intravenous infusion of ABL001/CTX‐009 diluted in 0.9% normal saline (250 mL) over 1 h. ABL001/CTX‐009 was administered in a 2‐week cycle, with the exception of the second dose, which had a 3‐week interval. Administration continued until unacceptable toxicity or disease progression was identified according to RECIST version 1.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior therapy, performance status, and tumor types
Endpoints
Registered primary outcome measure
Efficacy results
Responses, dose levels at which they occurred, and DLL4 expression
Response and disease control at the recommended phase 2 doses
Limitations
No evidence found.
Clinical guidelines
Guidelines make no recommendation for tovecimig; the ESMO Clinical Practice Guideline (2023) states an urgent need for new therapies in this setting
“Nearly 40% of patients with BTC harbour genetic alterations which are potential targets for precision medicine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There remains, therefore, an urgent need to develop new therapies, particularly for patients who lack a targetable genomic alteration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ESMO Clinical Practice Guideline (2023): second-line systemic therapy after cisplatin and gemcitabine
“FOLFOX is the SoC in the second-line setting after cisplatin–gemcitabine [I, A; ESMO-MCBS v1.1 score: 1; no specific licensed indication in BTC].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Second-line ChT has previously been used ad hoc by clinicians with limited knowledge of the magnitude of benefit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Evidence for irinotecan-based therapies is currently limited.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ESMO Clinical Practice Guideline (2023): tissue acquisition and the composition of the molecular testing panel
“A core biopsy should be obtained for diagnostic pathology and molecular profiling before any nonsurgical treatment [III, A].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with d/pCCA without extraductal metastasis, PTC- or ERCP-guided biopsies should be carried out to obtain adequate tissue for diagnostic pathology and molecular profiling [III, A].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Parallel sequencing of several genes using focused next-generation sequencing (NGS) is preferred over single gene testing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, the gene panel should include the respective coding DNA regions (target regions) of isocitrate dehydrogenase 1 (IDH1), human epidermal growth factor receptor 2 (HER2)/neu [v-erb-b2 avian erythroblastic leukaemia viral oncogene homologue 2 (ERBB2)] and BRAF to test for hotspot mutations, but the rapidly evolving landscape of drug targets and predictive biomarkers may soon necessitate larger panels.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pan-Asian adapted ESMO Clinical Practice Guidelines (2024): first-line alternatives, second-line chemotherapy, molecularly directed therapy, locoregional therapy, and supportive care
“Oxaliplatin or carboplatin may be substituted for cisplatin when renal or auditory function is of concern, while gemcitabine plus S-1 can be an option for patients who present with or are susceptible to peripheral sensory neuropathy [II, B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gemcitabine monotherapy may be used in patients with a PS of 2 [IV, B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FOLFOX is the standard of care in the second-line setting after cisplatin-gemcitabine-based treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Irinotecan monotherapy or irinotecan- or liposomal irinotecan-based combination therapy may be considered [III, B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, FOLFOX treatment showed a limited survival benefit compared with active symptom control (6.2 months for FOLFOX versus 5.3 months for active symptom control).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, because the ABC-06 trial is the only positive phase III trial for the second-line treatment of BTC, the LoE was also downgraded from ‘I’ to ‘II’.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ivosidenib is recommended for the treatment of patients with CCA and IDH1 mutations who have progressed after ≥1 prior line of systemic therapy [I, A; ESMO-MCBS v1.1 score: 2; ESCAT score: I-A; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FGFR inhibitors are recommended for the treatment of patients with FGFR2 fusions who have progressed after ≥1 prior line of systemic therapy [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HER2-directed therapies can be considered in patients with HER2 overexpression/amplification who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dabrafenib-trametinib is recommended for the treatment of patients with BRAFV600E mutations who have progressed after ≥1 prior line of systemic therapy [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NTRK inhibitors are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Selpercatinib can be considered in patients with RET fusions who have progressed on or are intolerant to prior treatment [III; A; ESMO-MCBS v1.1 score for solid tumours with a RET fusion: 3; ESCAT score: I-C; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab is recommended in patients with MSI-H/dMMR who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab can be considered in patients with TMB-H tumours who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment [IV; A; ESMO-MCBS v1.1 score for pembrolizumab in TMB-H solid tumours: 3; ESCAT Score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Local ablation could be considered as an option for patients with iCCA ≤3 cm who have contraindications or are otherwise unfit for surgery [III, B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SBRT can be considered for patients with iCCA in case of contraindication to surgery for liver-limited disease in the palliative setting [III, C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intraarterial therapies, in combination with systemic ChT, can be an option for patients with liver-limited iCCA and discussed by the MDTB according to local availability [III, C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with biliary obstruction, biliary drainage and subsequent treatment should be carried out; when endoscopic access is not possible, percutaneous transhepatic drainage is recommended [IV, A]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sepsis secondary to biliary obstruction is common and should be treated promptly [IV, A]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients should be advised of the likely duration of stent patency and of symptoms and signs which are indicative of biliary obstruction or infection [V, A]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pan-Asian adapted ESMO Clinical Practice Guidelines (2024): imaging, biomarkers, and molecular analysis that define the treated population
“Molecular analysis is recommended in advanced disease considered suitable for systemic treatment [I, A]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Elevated CA 19-9 is associated with poorer prognosis and can be useful for assessing response to treatment [III, C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thoraco-abdomino-pelvic CT remains the reference examination for lymph node and metastatic extension [III, A]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FDG-PET is not recommended for imaging of the primary tumour. However, it may be considered where there is clinical suspicion of nodal metastases, distant metastases and disease recurrence [III, C; consensus = 100%].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Radiological imaging should be carried out before ERCP or PTC in patients with jaundice [III, A]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESMO Clinical Practice Guideline interim update (2025): first-line chemoimmunotherapy and biomarker-directed later-line therapy
“Cisplatin–gemcitabine–durvalumab and cisplatin–gemcitabine–pembrolizumab are recommended as first-line therapy [I, A].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cisplatin–gemcitabine combined with either pembrolizumab or durvalumab is a viable option for first-line treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At present, there are no discernible clinical, biochemical or molecular biomarkers, nor any notable differences in efficacy or toxicity, favouring one immune checkpoint inhibitor over the other.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Higher rates of treatment-related toxicity are observed with the addition of a third cytotoxic agent to gemcitabine–cisplatin in all of these regimens.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Futibatinib [ESMO-Magnitude of Clinical Benefit (MCBS) v1.1 score: 3] and pemigatinib (ESMO-MCBS v1.1 score: 2) are recommended in patients with FGFR2 fusions or rearrangements who have progressed after one or more prior lines of systemic therapy [III, A; ESCAT score: I-B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings led to both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approval of pemigatinib and futibatinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zanidatamab is recommended in patients with previously treated HER2-positive disease [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C; FDA approved, not EMA approved].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Trastuzumab deruxtecan should be considered in patients with HER2 overexpression and/or HER2 amplification who have progressed on or are intolerant to prior treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C; FDA approved, not EMA approved].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zanidatamab is now FDA approved for previously treated, unresectable or metastatic HER2-positive BTC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HER2 alterations, comprising amplifications and mutations, as well as human epidermal growth factor receptor 2 (HER2) protein overexpression, can be found in ∼5%-10% of BTC cases, with a higher prevalence observed in extrahepatic CCA and gallbladder carcinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most clinical trials focus on patients with HER2 overexpression and HER2 amplification, yet there are currently no standardised criteria for assessing HER2 status in BTC and no specific test can be recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Entrectinib (ESMO-MCBS v1.1 score: 3), larotrectinib (ESMO-MCBS v1.1 score: 3) and repotrectinib (not EMA or FDA approved) are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Selpercatinib should be considered in patients with RET fusions who have progressed on or are intolerant to prior treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NTRK fusions occur in <0.1% of BTC cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because of the very low prevalence of these alterations, the respective inhibitors have only been evaluated in basket trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety summary
Contraindications
No approved labeling and therefore no labeled contraindications: tovecimig is an investigational product whose biologics license application is planned
Cardiovascular, hemorrhagic, and gastrointestinal conditions excluded from COMPANION-002
Boxed warning
No approved labeling and therefore no boxed warning: tovecimig is an investigational product whose biologics license application is planned
Warnings and precautions
No approved labeling and therefore no labeled warnings and precautions: tovecimig is an investigational product whose biologics license application is planned
Independent safety monitoring in COMPANION-002
Adverse event grading and safety follow-up specified in COMPANION-002
“Safety will be monitored throughout the study and for 30 days after the end of treatment. Adverse events will be assessed as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Class-related events reported with other DLL4 and VEGF bispecific antibodies
“The treatment related adverse events (≥15% of patients) were hypertension (57.6%), headache (28.8%), fatigue (25.8%), and pulmonary hypertension (18.2%). Pulmonary hypertension was mostly asymptomatic at doses ≤5 mg/kg (6 Gr1, 1 Gr2), but was more severe at higher doses (4 Gr2, 1 Gr3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twelve patients experienced pulmonary hypertension (6 asymptomatic Grade 1, 5 Grade 2 and 1 Grade 3) that was reversible upon drug discontinuation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Left-sided heart failure was the primary toxicity which limited the therapeutic index of the anti-DLL4 agents. Importantly, no cases of left-sided heart failure were observed in this study of dual DLL4/VEGF inhibition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There were 19 (28.8%) patients that had navicixizumab withdrawn because of an adverse event. The most common adverse event that resulted in navicixizumab being withdrawn were: pulmonary hypertension (7 [10.6%] patients); hypertension (4 [6.1%] patients); and infusion-related reactions, fatigue, and increased BNP (2 [3.0%] patients each).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Single agent activity has been observed with anti-DLL4 therapy, but treatment duration was limited by cardiotoxicity that is believed to be due to the increased vascular sprouting which occurs when DLL4 is inhibited, but VEGF is not inhibited” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hypertension management protocol and cardiac monitoring in the navicixizumab phase 1a study
“This dose level was expanded to 6 patients; of these, 4 patients discontinued from the study due to hypertension. As a result, a standardized protocol for hypertension management was established (initially using amlodipine or nifedipine at starting doses of 5 and 30 mg daily, when blood pressure was >140/90; ACE inhibitors or beta-blockers were added afterwards as needed) and 6 more patients were treated at 2.5 mg/kg without having to be withdrawn for hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with ≥ Grade 2 pulmonary hypertension were referred to a cardiologist or pulmonologist to determine what if any further evaluations and/or treatment for their pulmonary hypertension were warranted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Six patients had a BNP level > 250 pg/mL. Five of these patients had pulmonary hypertension which presumably caused the BNP elevation and 1 patient had a reduction in left ventricular ejection fraction (from 55 to 40%) without pulmonary hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Common adverse reactions
COMPANION-002: overall safety conclusion and most frequent events
COMPANION-002: treatment-emergent adverse events reported in at least 20% of participants, n (%), with the paclitaxel comparator arm
| Adverse event | Tovecimig plus paclitaxel (n=108), any grade | Tovecimig plus paclitaxel (n=108), grade 3 or higher | Paclitaxel (n=53), any grade | Paclitaxel (n=53), grade 3 or higher |
|---|---|---|---|---|
| Hypertension | “75 (69)” | “56 (52)” | “10 (19)” | “3 (6)” |
| Fatigue | “72 (67)” | “16 (15)” | “24 (45)” | “3 (6)” |
| Neutropenia | “59 (55)” | “40 (37)” | “20 (38)” | “14 (26)” |
| Diarrhea | “51 (47)” | “6 (6)” | “15 (28)” | “1 (2)” |
| Anemia | “48 (44)” | “23 (21)” | “17 (32)” | “5 (9)” |
| Decreased appetite | “44 (41)” | “2 (2)” | “11 (21)” | “-” |
| Nausea | “43 (40)” | “2 (2)” | “17 (32)” | “-” |
| Proteinuria | “37 (34)” | “3 (3)” | “5 (9)” | “-” |
| Vomiting | “36 (33)” | “1 (1)” | “13 (25)” | “1 (2)” |
| Abdominal pain | “35 (32)” | “9 (8)” | “13 (25)” | “4 (8)” |
| Dyspnea | “32 (30)” | “5 (5)” | “13 (25)” | “-” |
| Epistaxis | “32 (30)” | “-” | “4 (8)” | “-” |
| Alopecia | “32 (30)” | “-” | “28 (53)” | “-” |
| Thrombocytopenia | “33 (31)” | “7 (7)” | “6 (11)” | “-” |
| Peripheral edema | “35 (32)” | “-” | “7 (13)” | “-” |
| Peripheral neuropathy | “29 (27)” | “2 (2)” | “13 (25)” | “1 (2)” |
| Constipation | “30 (28)” | “-” | “8 (15)” | “-” |
| Headache | “25 (23)” | “-” | “7 (13)” | “-” |
| Arthralgia | “25 (23)” | “-” | “6 (11)” | “-” |
COMPANION-002: consistency of the safety profile across data cuts
Single-arm phase 1b/2 in South Korea: treatment-related adverse events
Single-arm phase 1b/2 in South Korea: treatment-emergent adverse events regardless of relationship
Single-arm phase 1b/2 in South Korea: adverse events of special interest
Phase 1 monotherapy dose escalation: dose-limiting toxicities and treatment-emergent adverse events
Phase 1 monotherapy dose escalation: tolerability across the dose range
Phase 2 monotherapy in colorectal cancer: hypertension
Drug interactions
Protocol restrictions on anticoagulants, antiplatelet agents, and prior anticancer therapy
“Current or recent (within 10 days prior to study treatment) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose will be excluded” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with current or recent (within 10 days of study treatment) use of aspirin (>81 mg/day), or other NSAIDs, or other antiplatelets (i.e., dipyridamole, ticlopidine, clopidogrel and cilostazol) will be excluded” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Less than 2 weeks have elapsed since patients had chemotherapy or hormone therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Covariates tested in the population pharmacokinetic analysis
“Except for body weight, no other covariate was determined as significant to the PK properties of ABL001/CTX‐009, and the body weight was assessed as a significant covariate for V1 by leading to the largest decrease in the OFV and was added as a covariate on V1 as below:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical interaction with cytotoxic chemotherapy through tumor vessel normalization
“Anti-VEGF therapy is known to normalize tumor blood vessels, leading to a more efficient delivery of cytotoxic anti-cancer agents into tumor tissues” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, because the VEGF-binding part of ABL001 is composed of the same IgG backbone and sequence as bevacizumab, ABL001 may have similar activity and function as bevacizumab in tumor vessels, resulting in a more effective delivery of anti-cancer agents, such as paclitaxel or irinotecan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dedicated clinical drug interaction studies
No evidence found.
Special populations
Eligibility restrictions applied in COMPANION-002
Contraception requirements
“Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile), or be at least 2 years postmenopausal, or commit to use two acceptable forms of birth control (defined as the use of an IUD, a barrier method with spermicide, condoms, or any form of hormonal contraceptives) or abstinence for the duration of the study and for 6 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 6 months following the last dose of study treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age, sex, and race of participants randomized in COMPANION-002
| Characteristic | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) |
|---|---|---|
| Median age, years | “65.0” | “63.0” |
| Male, n (%) | “53 (47.7)” | “24 (42.1)” |
| Female, n (%) | “58 (52.3)” | “33 (57.9)” |
| Asian, n (%) | “17 (15.3)” | “10 (17.5)” |
| White, n (%) | “84 (75.7)” | “40 (70.2)” |
| African American, n (%) | “4 (3.6)” | “6 (10.5)” |
| Unknown or other, n (%) | “6 (5.4)” | “1 (1.8)” |
Age and organ-function eligibility in the phase 1 study
“Adult patients (aged ≥19 years) with confirmed of any progressive locally advanced or metastatic solid tumors that had relapsed or were refractory to the standard therapy were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who had clinically significant cardiovascular disease, including pulmonary hypertension and myocardial infarction, hypersensitivity to humanized/human mAb, or who previously received anti‐DLL4 antibody were excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pediatric use, pregnancy and lactation, and dedicated renal or hepatic impairment pharmacokinetic studies
No evidence found.
Comparators and place in therapy
Absence of an approved systemic therapy in the second line outside biomarker-directed agents
FOLFOX: guideline standing and reported outcomes in the second line
“FOLFOX is the standard of care in the second-line setting after cisplatin-gemcitabine-based treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Irinotecan monotherapy or irinotecan- or liposomal irinotecan-based combination therapy may be considered [III, B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients who progressed after frontline therapy and lack actionable alterations, fluoropyrimidine plus oxaliplatin and fluoropyrimidine plus liposomal irinotecan are recommended second-line options, supported by ABC-06 and NIFTY, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint, median OS, was significantly improved with ASC plus FOLFOX over ASC alone (Table 1B). The median PFS was 4.0 months, and the ORR was 4.9% in the FOLFOX arm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“FOLFOX is the SoC in the second-line setting after cisplatin–gemcitabine [I, A; ESMO-MCBS v1.1 score: 1; no specific licensed indication in BTC].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Second-line ChT has previously been used ad hoc by clinicians with limited knowledge of the magnitude of benefit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Evidence for irinotecan-based therapies is currently limited.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival was significantly longer in the ASC plus FOLFOX group than in the ASC alone group, with a median overall survival of 6·2 months (95% CI 5·4–7·6) in the ASC plus FOLFOX group versus 5·3 months (4·1–5·8) in the ASC alone group (adjusted hazard ratio 0·69 [95% CI 0·50–0·97]; p=0·031).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Objective response was observed in four (5%) of 81 patients in the ASC plus FOLFOX group: one (1%) patient had a complete response and three (4%) patients had a partial response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3–5 adverse events were reported in 42 (52%) of 81 patients in the ASC alone group and 56 (69%) of 81 patients in the ASC plus FOLFOX group, including three chemotherapy-related deaths (one each due to infection, acute kidney injury, and febrile neutropenia).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on these findings, FOLFOX should become standard-of-care chemotherapy in second-line treatment for advanced biliary tract cancer and the reference regimen for further clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Downgraded strength of the second-line chemotherapy recommendation
“Furthermore, FOLFOX treatment showed a limited survival benefit compared with active symptom control (6.2 months for FOLFOX versus 5.3 months for active symptom control).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, because the ABC-06 trial is the only positive phase III trial for the second-line treatment of BTC, the LoE was also downgraded from ‘I’ to ‘II’.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Liposomal irinotecan-based regimens: NIFTY, NALIRICC, and pooled individual patient data
“At a median follow-up of 11·8 months (IQR 7·7-18·7), the median BICR-assessed progression-free survival was significantly longer in the liposomal irinotecan plus fluorouracil and leucovorin group (7·1 months, 95% CI 3·6-8·8) than in the fluorouracil and leucovorin group (1·4 months, 1·2-1·5; hazard ratio 0·56, 95% CI 0·39-0·81; p=0·0019).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Liposomal irinotecan plus fluorouracil and leucovorin could be considered a standard-of-care second-line therapy for advanced biliary tract cancer.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The discordance rate for the date of tumour progression between the investigator and the BICR assessments was 30% (52 of 174; appendix 2 pp 5–8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the possibility of overestimation in the median progression-free survival by BICR assessment cannot be excluded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival was 2·6 months (95% CI 1·7-3·6) in the nanoliposomal irinotecan group and 2·3 months (1·6-3·4) in the control group (hazard ratio [HR] 0·87 [0·56-1·35]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The addition of nanoliposomal irinotecan to fluorouracil plus leucovorin did not improve progression-free survival or overall survival and was associated with higher toxicity compared with fluorouracil plus leucovorin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Differences in sample size (174 vs. 100), iCCA proportion (64% vs. 43%), ethnicity (Asian vs. White), and more frequent early treatment discontinuations due to toxicity in NALIRICC may have contributed to the discordant results [28].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Current standard of care for second-line therapy in patients with advanced biliary tract cancer (BTC) is FOLFOX.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The nal-IRI plus 5-FU/LV group showed significantly longer median PFS (3.6 months [95% CI 2.7-4.4] vs. 1.8 months [95% CI 1.5-2.6]; hazard ratio 0.65, p <0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was no statistically significant difference in OS (median 8.1 vs. 6.1 months, HR 0.77, p = 0.051).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, nal-IRI plus 5-FU/LV may be considered a viable alternative to second-line FOLFOX for patients of East Asian ethnicity or those deemed unfit for FOLFOX (e.g. due to severe peripheral neuropathy caused by prior platinum-based therapy).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Taxane-based chemotherapy in later-line practice and the rationale for the paclitaxel comparator
“Treatment distribution was as follows: FOLFIRI (n = 51, 20%), paclitaxel (n = 43, 17%), combinations of 5-FU cisplatin/FOLFOX (n = 32, 13%), molecularly targeted therapy (n = 65, 25%) and others (n = 63, 25%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OS was 13 months with paclitaxel and 7 months with FOLFIRI (P = 0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second-line options for biliary tract cancer (BTC) are limited. While nab-paclitaxel has demonstrated certain antitumor activity, evidence remains scarce.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 84 patients (41 in the chemo-anti-PD-(L)1 group and 43 in the chemotherapy group), the median OS was 15.17 months (95% confidence interval (CI), 12.63-21.43), median PFS was 5.40 months (95% CI, 3.23-8.03), objective response rate (ORR) was 21.43% (95% CI, 13.22-31.74), and disease control rate (DCR) was 60.71% (95% CI, 49.45-71.20).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Paclitaxel was chosen based on the safety and efficacy data from this phase Ib study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point of the phase II study was overall response rate (ORR) and the ORR was 37.5% (n = 9/24 patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 11 patients treated in the second-line, the ORR was 63.6% (n = 7/11) versus 15% (n = 2/13) among patients treated in the third-line setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tovecimig plus paclitaxel compared with paclitaxel alone in COMPANION-002
Share of patients eligible for a biomarker-directed option
“Nearly 40% of patients with BTC harbour genetic alterations which are potential targets for precision medicine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There remains, therefore, an urgent need to develop new therapies, particularly for patients who lack a targetable genomic alteration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A treatment option is urgently needed for patients with tumors without an obvious actionable alteration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While several targeted therapies have gained approval for addressing gene alterations that are relevant in BTC, only a minority of BTCs harbor these alterations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a randomized study in the second-line setting, the three drug combination regimen FOLFOX improved median overall survival by 0.9 months compared with best supportive care” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FGFR2 fusion-directed inhibitors: prevalence, recommendations, and reported outcomes
“Fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory ctDNA analysis identified FGFR2 fusions or rearrangements in 83 of the 95 patients (87%) evaluated” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Futibatinib [ESMO-Magnitude of Clinical Benefit (MCBS) v1.1 score: 3] and pemigatinib (ESMO-MCBS v1.1 score: 2) are recommended in patients with FGFR2 fusions or rearrangements who have progressed after one or more prior lines of systemic therapy [III, A; ESCAT score: I-B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings led to both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approval of pemigatinib and futibatinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FGFR inhibitors are recommended for the treatment of patients with FGFR2 fusions who have progressed after ≥1 prior line of systemic therapy [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR in cohort A was 37.0% (95% confidence interval 27.9% to 46.9%); complete and partial responses were observed in 3 and 37 patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median DOR was 9.1 (6.0-14.5) months; median PFS and OS were 7.0 (6.1-10.5) months and 17.5 (14.4-22.9) months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAEs of any grade were hyperphosphatemia (58.5%), alopecia (49.7%), and diarrhea (47.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 43 of 103 patients (42%; 95% confidence interval, 32 to 52) had a response, and the median duration of response was 9.7 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At a median follow-up of 17.1 months, the median progression-free survival was 9.0 months and overall survival was 21.7 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Common treatment-related grade 3 adverse events were hyperphosphatemia (in 30% of the patients), an increased aspartate aminotransferase level (in 7%), stomatitis (in 6%), and fatigue (in 6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, treatment-related adverse events led to dose interruptions in 52 patients (50%) and dose reductions in 56 patients (54%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cholangiocarcinoma is a rare, aggressive cancer often driven by FGFR2 fusions, which are targetable with inhibitors such as pemigatinib and futibatinib. However, resistance frequently develops due to acquired FGFR2 mutations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 51 patients included in the efficacy evaluable set, the objective response rate was 6·3% (95% CI 0·2-30·2; one confirmed partial response) in cohort A1, 30·0% (6·7-65·3; three confirmed partial responses) in cohort A2, 23·1% (5·0-53·8; three confirmed partial responses) in cohort B, and 0% in cohort C.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
IDH1 inhibition: recommendation and ClarIDHy results
“Ivosidenib is recommended for the treatment of patients with CCA and IDH1 mutations who have progressed after ≥1 prior line of systemic therapy [I, A; ESMO-MCBS v1.1 score: 2; ESCAT score: I-A; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Progression-free survival was significantly improved with ivosidenib compared with placebo (median 2·7 months [95% CI 1·6-4·2] vs 1·4 months [1·4-1·6]; hazard ratio 0·37; 95% CI 0·25-0·54; one-sided p<0·0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 10.3 months (95% CI, 7.8-12.4 months) with ivosidenib vs 7.5 months (95% CI, 4.8-11.1 months) with placebo (hazard ratio, 0.79 [95% CI, 0.56-1.12]; 1-sided P = .09).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When adjusted for crossover, median OS with placebo was 5.1 months (95% CI, 3.8-7.6 months; hazard ratio, 0.49 [95% CI, 0.34-0.70]; 1-sided P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HER2-directed therapy: alteration frequency, recommendations, and reported outcomes
“HER2 alterations, comprising amplifications and mutations, as well as human epidermal growth factor receptor 2 (HER2) protein overexpression, can be found in ∼5%-10% of BTC cases, with a higher prevalence observed in extrahepatic CCA and gallbladder carcinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most clinical trials focus on patients with HER2 overexpression and HER2 amplification, yet there are currently no standardised criteria for assessing HER2 status in BTC and no specific test can be recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Between Sept 15, 2020, and March 16, 2022, 847 patients were pre-screened for HER2 amplification and 171 (20%) had HER2-amplified tumours, of which 131 (77%) entered study screening and 87 (66%) were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HER2 gene amplification status was determined by the VENTANA HER2 Dual ISH DNA Probe Cocktail assay (Ventana Medical Systems, Tuscon, AZ, USA). HER2 gene status was classified as non-amplified (HER2/Chr17 ratio <2·0) or amplified (HER2/Chr17 ratio ≥2·0).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Zanidatamab is recommended in patients with previously treated HER2-positive disease [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C; FDA approved, not EMA approved].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Trastuzumab deruxtecan should be considered in patients with HER2 overexpression and/or HER2 amplification who have progressed on or are intolerant to prior treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C; FDA approved, not EMA approved].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zanidatamab is now FDA approved for previously treated, unresectable or metastatic HER2-positive BTC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HER2-directed therapies can be considered in patients with HER2 overexpression/amplification who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Confirmed objective responses by independent central review were observed in 33 patients in cohort 1 (41·3% [95% CI 30·4-52·8]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median duration of response for the 33 patients in cohort 1 with a confirmed objective response was 12·9 months (95% CI 6·0–not estimable; range 1·5–16·9+) with 16 (49%) patients having ongoing responses at the time of the data cutoff (figure 2B; appendix p 5). No responses to zanidatamab were observed in cohort 2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median progression-free survival by independent central review in cohort 1 was 5·5 months (95% CI 3·7–7·2; range 0·3–18·5+; table 2; appendix p 6). Overall survival at 9 months was 69·9% (95% CI 57·8–79·1) for cohort 1; median overall survival data were immature at the time of data cutoff.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“16 patients (18%) had grade 3 treatment-related adverse events; of these, diarrhoea (four [5%] patients), ejection fraction decreased (three [3%]), and anaemia (two [2%]) occurred in more than one patient. No grade 4 or grade 5 treatment-related adverse events were reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with central HER2 IHC 3+ expression (n = 75), the ORR was 61.3% (95% CI, 49.4 to 72.4), the median DOR was 22.1 months (95% CI, 9.6 to not reached), the median PFS was 11.9 months (95% CI, 8.2 to 13.0), and the median OS was 21.1 months (95% CI, 15.3 to 29.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade ≥3 drug-related adverse events were observed in 40.8% of patients; 10.5% experienced adjudicated drug-related interstitial lung disease (ILD), with three deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cORR was 46.7% (90% CI, 30.8 to 63.0), with a disease control rate of 76.7% (90% CI, 60.6 to 88.5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median duration of response and progression-free survival were 6.0 months (90% CI, 5.5 to 6.9) and 5.5 months (90% CI, 3.9 to 8.1), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At data cutoff, 15 patients (50.0%) had died, and the estimated 12-month overall survival rate was 53.6% (90% CI, 36.8 to 67.8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor-agnostic targeted and immune therapies: target frequency and recommendations
“Disease-agnostic approved agents are available for tumors with BRAF V600E mutations (4–5% frequency in BTC), NTRK fusions (<1%), RET fusions (<1%), and/or microsatellite instability (1–2%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NTRK fusions occur in <0.1% of BTC cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because of the very low prevalence of these alterations, the respective inhibitors have only been evaluated in basket trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dabrafenib-trametinib is recommended for the treatment of patients with BRAFV600E mutations who have progressed after ≥1 prior line of systemic therapy [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NTRK inhibitors are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Selpercatinib can be considered in patients with RET fusions who have progressed on or are intolerant to prior treatment [III; A; ESMO-MCBS v1.1 score for solid tumours with a RET fusion: 3; ESCAT score: I-C; FDA approved, not EMA approved]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab is recommended in patients with MSI-H/dMMR who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab can be considered in patients with TMB-H tumours who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment [IV; A; ESMO-MCBS v1.1 score for pembrolizumab in TMB-H solid tumours: 3; ESCAT Score: I-C]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Entrectinib (ESMO-MCBS v1.1 score: 3), larotrectinib (ESMO-MCBS v1.1 score: 3) and repotrectinib (not EMA or FDA approved) are recommended in patients with NTRK fusions who have progressed on or are intolerant to prior treatment [III, A; ESCAT score: I-C].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Selpercatinib should be considered in patients with RET fusions who have progressed on or are intolerant to prior treatment [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-C].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An investigator-assessed overall response was achieved by 22 (51%, 95% CI 36-67) of 43 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An independent reviewer-assessed overall response was achieved by 20 (47%, 95% CI 31-62) of 43 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median duration of response in 22 patients with an investigator-assessed overall response was 9 months (95% CI 6–14).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival by investigator assessment was 9 months (95% CI 5–10; figure 2A). Overall survival was 84% (95% CI 69–92) at 6 months, 56% (38–71) at 12 months, and 36% (19–53) at 24 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“15 (35%) patients had adverse events that led to dose reduction, 24 (56%) patients had adverse events that led to dose interruption” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Line of therapy and eligibility without positive biomarker selection
“Patients who are eligible to be treated with a molecularly targeted therapy on a labelled regimen after receiving first-line chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stratification factors include stage (locally advanced vs metastatic), anatomic subtype of the primary tumor (intrahepatic cholangiocarcinoma vs other) and ECOG performance status (0 or 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients are randomized to a 2:1 ratio, and crossover is allowed to the experimental arm at the time of progression in the control arm for patients that continue to meet eligibility criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting and administration schedule anticipated for tovecimig
| Field | Registry record |
|---|---|
| Official title | “A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen” |
| Intervention description, CTX-009 | “IV infusion on day 1 and 14 of every 28 day cycle” |
| Intervention description, paclitaxel | “IV infusion on day 1, 8, and 15 of every 28 day cycle” |
| Comparator arm description | “Patients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1.” |
| Overall status | “Active, not recruiting” |
Absence of a direct head-to-head comparison against an active second-line regimen
No evidence found.
Conclusion
Unmet need in the population that would receive tovecimig
“Nearly 40% of patients with BTC harbour genetic alterations which are potential targets for precision medicine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There remains, therefore, an urgent need to develop new therapies, particularly for patients who lack a targetable genomic alteration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Strongest reported efficacy result: objective response rate in the final analysis of COMPANION-002
Supporting result: progression-free survival
Constraint on those results: the overall survival endpoint was not met and the crossover-adjusted analysis is stated to be uninterpretable
Regulatory standing: designations granted and a submission not yet filed
Current status of the product
References
- Abou-Alfa et al. (2020) (opens in a new tab)
- Azad et al. (2024) (opens in a new tab)
- Azad et al. (2026) (opens in a new tab)
- Banales et al. (2020) (opens in a new tab)
- Boilève et al. (2026) (opens in a new tab)
- Brindley et al. (2021) (opens in a new tab)
- CancerNetwork (2026) (opens in a new tab)
- Chen et al. (2024b) (opens in a new tab)
- ClinicalTrials.gov NCT03292783 (opens in a new tab)
- ClinicalTrials.gov NCT04492033 (opens in a new tab)
- ClinicalTrials.gov NCT05506943 (opens in a new tab)
- ClinicalTrials.gov NCT06548412 (opens in a new tab)
- Compass Therapeutics COMPANION-002 data presentation (2026) (opens in a new tab)
- Compass Therapeutics COMPANION-002 primary endpoint announcement (2025) (opens in a new tab)
- Compass Therapeutics COMPANION-002 survival data announcement (2026) (opens in a new tab)
- Compass Therapeutics corporate presentation (2026) (opens in a new tab)
- Compass Therapeutics Fast Track designation announcement (2024) (opens in a new tab)
- Compass Therapeutics first quarter results announcement (2026) (opens in a new tab)
- Compass Therapeutics Form 10-K (2026) (opens in a new tab)
- Compass Therapeutics Form 10-Q (2026) (opens in a new tab)
- Compass Therapeutics regulatory update announcement (2026) (opens in a new tab)
- Compass Therapeutics second quarter results announcement (2026) (opens in a new tab)
- Compass Therapeutics third quarter results announcement (2026) (opens in a new tab)
- Gordon et al. (2021) (opens in a new tab)
- Goyal et al. (2023) (opens in a new tab)
- Harding et al. (2023) (opens in a new tab)
- Javle et al. (2022) (opens in a new tab)
- Javle et al. (2026) (opens in a new tab)
- Jimeno et al. (2019) (opens in a new tab)
- Korea Biomedical Review (2026) (opens in a new tab)
- Lamarca et al. (2021) (opens in a new tab)
- Lamarca et al. (2026) (opens in a new tab)
- Lee et al. (2021) (opens in a new tab)
- Meric-Bernstam et al. (2024) (opens in a new tab)
- Na et al. (2024) (opens in a new tab)
- Nakamura et al. (2023) (opens in a new tab)
- Oh et al. (2023) (opens in a new tab)
- Parasuraman et al. (2023) (opens in a new tab)
- SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026) (opens in a new tab)
- Siegel et al. (2026) (opens in a new tab)
- Subbiah et al. (2020) (opens in a new tab)
- Vogel and Ducreux (2025) (opens in a new tab)
- Vogel et al. (2023) (opens in a new tab)
- Vogel et al. (2024a) (opens in a new tab)
- Vogel et al. (2024b) (opens in a new tab)
- Wang et al. (2024) (opens in a new tab)
- Yeom et al. (2020) (opens in a new tab)
- Yoo et al. (2021) (opens in a new tab)
- Yoo et al. (2025a) (opens in a new tab)
- Yoon and Yoo (2026) (opens in a new tab)
- Zhou et al. (2025) (opens in a new tab)
- Zhu et al. (2021) (opens in a new tab)